Chenguang Tianrun Pharmaceutical was established on May 24, 2019. It is an enterprise focusing on the research and development, production and sales of raw materials and pharmaceutical intermediates. On July 11, 2024 and September 23, 2024, sodium valproate and valproic acid raw materials were successfully accepted by the National Medical Products Administration, marking a major step forward for Tianrun Pharmaceutical in the field of raw materials.

Sodium valproate, also known as sodium dipropylacetate, is an organic compound commonly used to treat mental illnesses such as epilepsy, bipolar disorder and bipolar disorder. Sodium valproate exists in a variety of dosage forms, including tablets, injections, syrups, powder injections, etc. It works by affecting the activity of neurotransmitters in the brain, mainly affecting the balance of glutamate and GABA.

The discovery of sodium valproate can be traced back to the 1960s, when scientists discovered that it had anticonvulsant effects on animals. After further research, it was found that it also has a good rehabilitation effect on human epilepsy. Since then, sodium valproate has been widely used to treat various mental illnesses. Currently, sodium valproate has become the most widely prescribed anti-epileptic drug in the world.